Objective: The exact cell of origin of subependymal giant cell astrocytoma is debated but most currently consider the tumor in the astrocytic category. Mutations and subsequent biallelic inactivation of TSC1 encoding hamartin, or TSC2 encoding tuberin appear to be the underlying genetic aberrations. inactivation leads to loss of proteins that inhibit mammalian target of rapamycin (mTor) disrupting tightly regulated cell functions.
InTRODUCTIOn
Subependymal giant cell astrocytomas (SEGas) are benign, indolent, intraventricular tumors made up of large gemistocytic cells with an apparent astrocytic phenotype. SEGas occur in association with tuberous sclerosis, most commonly in children and young adults. The Tuberous Sclerosis Complex (TSC) is an autosomal dominant syndrome that also occurs in many patients with no previous family history, indicating a high sporadic mutation rate for these genes (1) . The disease manifests as multiple hamartomas, which form in the heart, brain, kidney and skin. The genes involved in tuberous sclerosis include TSC1 encoding the hamartin protein, and TSC2 encoding the tuberin protein. Mutations and subsequent biallelic inactivation of either TSC1 (located at 9q34) or TSC2 (located at 16p13) have been demonstrated in SEGas (2) . LoH more commonly involves TSC2 (57%) compared to TSC1 (4%); although LoH is less common in brain lesions (4%), it is much more common in renal angiomyolipomas and cardiac rhabdomyomas (56%) (3) (4) (5) . Biallelic inactivation is suggested to lead to the loss of proteins that inhibit mammalian target of rapamycin (mTor) disrupting a large number of tightly regulated cell functions (6, 7) . Previous studies have shown that the inactivation of TSC1 or TSC2 genes can be demonstrated in numerous sporadic tumor types in multiple organ systems (8) (9) (10) . Dysregulation of the mTor pathway appears to be primarily due to TSC gene inactivation in SEGas. Studies have illustrated the link between mTor dysregulation and the phosphorylation of its downstream substrates rPS6 and 4EBP-1 (11, 12) . These two downstream proteins, when phosphorylated, positively regulate the translation of proteins important for cell growth and replication ( Figure 2 ) (1).
Currently, SEGa is considered among the astrocytic neoplasms by the WHo classification system and is described as a slowly growing tumor composed of "ganglioid astrocytes". Earlier studies concerning the origin of SEGa supported the current classification of this tumor as a variant of astrocytoma due to a lack of significant neuronal specific marker expression and fairly consistent presence of GFaP (13) . Tumors found to be GFaP negative in these early studies were exclusively found in patients that also had tuberous sclerosis (13, 14) . This interesting finding was hypothesized to be the result of specific gene mutations in tuberous sclerosis, which may result in an inability to produce GFaP (13) . Later studies, including the data presented here, have shown variable presence of both glial and neuronal specific markers in SEGas with and without TSC mutations (15) . Thus, the exact cell of origin for SEGas is debatable since the neoplasms demonstrate evidence of divergent differentiation despite their mainly astrocytic appearance (15) (16) (17) .
While most SEGas are easy to recognize on morphological grounds, some larger tumors or smaller samples may be diagnostically challenging and may raise other possibilities such as "gemistocytic astrocytoma" or pleomorphic xanthoastrocytoma. in order to determine the practical diagnostic value in identifying the mutated protein and aid in differential diagnosis, we analyzed the expression of tuberin and hamartin proteins in 9 patients with SEGa diagnosed within our institution between 1996 and 2010 (Table i ). in addition, we evaluated the immunohistochemical expression of phosphorylated rPS6 and 4EBP1 regulatory proteins that are downstream to the hamartin-tuberin heterodimer in the mTor pathway. Finally, we analyzed a set of common neuroepithelial and tumor-associated markers such as isocitrate dehydrogenase 1 and 2 (iDH1 and iDH2) mutations shown to be common in infiltrating astrocytomas.
MATERIAL and METhODS
Patients-We have searched the department of pathology archives for any patient diagnosed with subependymal giant cell astrocytoma (SEGa) between 1996 and 2010. inclusion criteria for patients in the study were a previous diagnosis of SEGa with sufficient tumor tissue and clinical information. Consultation cases without available paraffin tissue, small samples and cases without sufficient clinical information were excluded. appropriate permission for the study was obtained from the Committee for Human research (CHr) of our institution (CHr no 10-00028).
Immunohistochemistry -Paraffin embedded tissue blocks were collected from the division of neuropathology and 1 referred case from another institution (patient #9). 4-6 micron thick tissue sections were cut from the tissue blocks and applied to slides. The tissue was deparaffinized in xylene using three changes for 5 minutes each. Sections were hydrated gradually through graded alcohols: washed in 100% ethanol twice for 10 minutes each, then 95% ethanol twice for 10 minutes each. Finally, the tissue was washed in deionized H 2 o for 1 minute with stirring and excess liquid was then aspirated from the slides. after antibody exposure, immunoperoxidase staining was performed utilizing a preformed avidin-biotinylated horseradish peroxidase complex as a detection reagent. The following antibodies were used on the prepared SEGa tissue specimens: Hamartin and Tuberin (polyclonal antibodies raised against n-terminus amino acids 1-300 of the respective human proteins, Santa Cruz Biotechnology inc, dilutions 1:50 for PCR analysis of IDH1 and IDH2 genes-formalin fixed, parafin embedded (FFPE) specimens were micro dissected to isolate tumor cells (when necessary), deparaffinized, digested (in a 56° C water bath for a minimum of 48 hours) and extracted using Qiagen Dna Mini Kit. Dna was quantified using a nanodrop spectrophotometer. PCr was subsequently performed on an aBi 9700 thermocycler in a 20uL total volume reaction containing: 200 ng Dna; 1x roche 480 Probes Master Mix®; 0.30 µM primers [iDH1 Exon 2 (Forward: TaTTCTGGGTGGCaCGGTCT, reverse: GGTCTTTaaaGGTTGaaCaTa CaC); iDH2 Exon 4 (Forward: GCTGCaGTGGGaCC aCTaTT, reverse: GaGaCGTC aTGTTC CGGTGT)]. PCr cycling conditions were constructed as follows: 1. Denaturing at 95° C for 2 min., 2. 35 cycles including 95° C for 0.5 min, 56° C for 0.5 min, 72° C for 0.5 min, and extension at 72° C for 7 min., 3. Cooling at 4° C on hold setting. PCr products were then purified using affymetrix/usb ExoSaP-iT (Santa Clara, Ca). Specimen was then diluted out 1:3 with highgrade water. Cycle sequencing was subsequently performed using aBi Big Dye Terminator v1.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, Ca) in a 10uL reaction using: 1.0 μl Big Dye® Terminator v1.1, 0.5 μl primer (10 pmol/ μl working concentration), and 1.0 μl amplicon; on an aBi 9700 thermocycler. Big Dye cycling conditions were constructed as follows: 1. Hold for 1 min at 96° C., 2. 25 cycles including 96° C for 10 sec, 50° C for 5 sec, and 60° C for 1 min. 3. Hold at 4° C. Big Dye® Terminator reaction products were purified using Princeton Separations CEnTri-SEP spin columns (Princeton Separations, adelphia, nJ) and subsequently run on an aBi 3130 sequencer for analysis. Table i shows clinical information pertaining to all 9 patients from which our SEGa specimens were collected. The male: female ratio was 5:4 with an age at diagnosis range of 1 to 57 years old. Tuberous sclerosis gene mutations were found in 6/9 patients, while 2 of the 9 patients were found to have normal genes and patient 9 status was yet to be determined. all patients who tested positive for tuberous sclerosis gene mutations were found to have either comorbid cortical or subependymal nodules and tubers, while the two patients testing negative for the gene mutations had no comorbid findings. Those who tested positive for gene mutations also experienced seizures as a primary symptom while those who tested negative did not have seizures. Patient treatment information included subtotal resection with radiosurgery (STR+Rad), subtotal resection alone (STR) or gross total resection alone (GTR). Follow-up time (F/U) varied from 26 to 173 months with only one confirmed fatality with patient 2. Confirmed recurrence or progression was confirmed in 3 of the 9 patients. Unk indicates unknown at this time. Hamartin and tuberin expression was found to be relatively decreased in SEGa specimens compared to control tissue (Table ii, Figure 2 ). rPS6 and 4EBP1 expression was found to be greater in SEGa specimens compared to control (Table ii, Figure 2 ). GFaP was strongly positive in only half of the cases (Table ii, Figure 3 ). Synaptophysin was positive in all tumors. Staining for CD34 (a marker often observed in well differentiated glio-neuronal tumors) and olig2 (a nuclear
RESULTS
There were 5 male and 4 female patients with a median age at diagnosis of 16 years (range: 1 to 57 years; see Table  i ). Tuberous sclerosis gene mutations were confirmed in six of the nine patients, while two patients were found to have normal TSC genes and the genetic status of patient #9 was pending at the time of this report. all patients who tested positive for tuberous sclerosis gene mutations were found to have either comorbid cortical or subependymal nodules and tubers, while the two patients testing negative for the gene mutations had no comorbid findings ( Figure  1 Table ii shows immunohistochemistry results for all 9 SEGa specimens and the 2 non-pathological controls (from recent autopsy archives). Strong GFaP positivity was observed in 5 specimens with weak staining of 1 specimen and negative staining of the remaining 3 SEGas. Synaptophysin was found to be positive in all 9 specimens while olig2 and CD34 were found to be entirely negative in all specimens. Ki67 staining of the 9 SEGas showed a low proliferation rate, which ranged from 2% to 8%. SEGa staining for hamartin, tuberin, rPS6-P, and P-4EBP-1 were subjectively rated on a scale from 0 to 3+ based on comparison with control staining. Hamartin and tuberin staining of all 9 SEGas showed decreased intensity (range 1+ to 2+) when compared to control (3+). rPS6-P and P-4EBP-1 staining of all 9 SEGas showed increased intensity (range 1+ to 2+) when compared to control (0). marker present in most gliomas) were entirely negative in all tumor cells (Table ii, Figure 3) . all of the tumors stained with the neurofilament antibody were predominantly negative except for focal neurofılament positivity along the periphery where the tumors have an indistinct border with the neuropil. Ki-67 (MiB-1) showed a low proliferation rate ranging from 2% to 8% (only one case at 8%) supporting the indolent growth pattern of these tumors. The tumor with the highest Ki-67 labeling index had no evidence of recurrence or aggressive growth.
PCr analysis for mutations of iDH1 and iDH2 (often present in low grade infiltrating gliomas) were entirely negative in all tumor cells.
DISCUSSIOn
our study aimed at using the recently developed antibodies for hamartin and tuberin as adjuncts to pathological as well as molecular diagnosis. We had initially hoped that it would be possible to determine the missing protein at the immunohistochemical level to aid in the recognition of patients with TSC. our results suggest that staining for either hamartin or tuberin is unlikely to be of diagnostic value due to positivity in almost all tumors and normal tissues, even if the expression is relatively decreased in SEGa as expected. it is also of interest that even in the setting of TSC1 or TSC2 gene mutations, the protein is unlikely to be entirely absent from SEGa cells, thereby negating the diagnostic value of detecting the gene products. an interesting observation with these antibodies was the fact that two of the SEGas without either TSC1 or TSC2 mutations had near-identical immunohistochemical staining profile with respect to hamartin and tuberin. These results may imply technical challenges, but also suggest that the expression of these proteins in SEGas is regulated in a more complex way than we presumed.
one possible explanation for presence of weakly positive immunostaining includes inactivation of the TSC heterodimer by tuberin phosphorylation by akt (18) or Erk (19) in cases without TSC gene mutations. Both akt and Erk kinases are located upstream of the TSC complex and are known to phosphorylate tuberin (TSC-2), which is thought to inhibit the GTPase enhancing activity resulting in mTor activation (Figure 4) . Therefore, activation of either of these two upstream kinases may result in mTor dysregulation similar to that seen with TSC gene mutations. More specifically, it has previously been shown that Erk Hamartin and tuberin antibody staining of SEGa specimens show only slightly decreased intensity compared to control staining when analyzed as a group. However, as seen in figure, they were not helpful in individual cases to determine whether there was a loss of the protein in SEGas. rPS6-P and P-4EBP-1 antibody staining of SEGa specimens show significant increased intensity compared to normal controls, suggesting activation of the pathways downstream to mTor. . it is possible that the staining results obtained in our study reflect a technical problem or an aberration in the fixation pattern of paraffin blocks giving a false negative result. To account for this possibility, we have repeated all negative cases and have used pepsin digestion as an alternate method if the stain was still negative after two trials. in addition, two of the pathology specimens included small fragments of neuropil within the blocks, which showed strong unequivocal GFaP staining. While it is still possible that technical mishaps may account for the staining results in rare cases, we believe that GFaP staining can be truly negative in some SEGas. our results are in agreement with Ess and colleagues who found GFaP positive staining in 50% (4/8) of the SEGas they analyzed (15) . The results of their work illustrated the inconsistent presence of both glial and neuronal developmental markers in all their tumors and suggested SEGas may develop from postnatally active neuroglial progenitor cells activation is present in all SEGas and may also play a crucial role in tumor formation in tuberous sclerosis patients (19) . our data support the observations of other groups, which have shown that LoH is uniquely sporadic in SEGas when compared to other tumors in TSC patients (3) (4) (5) .
The increased rPS6 and 4EBP1 immunostaining further confirms the activation of the mTor pathway and the possible role these molecules may have in the growth of SEGas, as previously suggested (1) . This finding also implies that hamartin and tuberin detected on immunohistochemical studies are most likely dysfunctional molecules unable to inhibit activation of the mTor pathway. our results further justify the use of rapamycin to control growth subtotally resected or non-resectable SEGas (20) (21) (22) .
in our experience, olig-2 antibody has emerged as a quite reliable and easily interpretable marker of glial differentiation in diagnostic surgical neuropathology (23) . in some instances where GFaP was not helpful, olig-2 has greatly helped in the recognition of glial differentiation in tumors (unpublished observations). We have also presumed that olig-2 could be another helpful marker in tumors where GFaP has been negative, but our results demonstrate complete absence of this nuclear stain in SEGas. This finding is quite interesting, when combined with the results of the GFaP antibody that some SEGas (15). Buccoliero et al. also showed variable staining with synaptophysin between different cell types in 8/9 of the tumors they tested, while we found 100% (9/9) positive staining in our specimens with variable staining observed between the three primary cell types. additionally, we also found all of our tumors to be entirely negative for CD34 (which is often positive in well-differentiated glio-neuronal tumors) and the tumors to be mostly negative for nF. This supports the results of You et al. (24) who found all of their tumors (8/8) to be negative for nF, but is at odds with the findings of Sharma et al., (17) who found positive staining in 15/15 SEGa specimens. This may relate to the type of antibody used in the studies.
our observations as well as observations of others mentioned above imply that SEGa may be considered more of a glioneuronal neoplasm than a pure astrocytic tumor in a broader sense. Further evidence and more conclusive data are required to make a more definitive statement about the actual cell of origin in SEGas and their appropriate place in the WHo classification scheme.
in addition to immunohistochemical analysis, we also investigated the possible presence of the isocitrate dehydrogenase gene (iDH1 and iDH2) mutations, which have recently, been shown to be present in 70-80% of diffuse low-grade infiltrating gliomas (25) (26) (27) (28) . as of today, the tumors that have been found to carry this mutation were predominantly infiltrating neoplasms, while circumscribed tumors such as pilocytic astrocytoma had wild-type genes (28) . iDH1 is the most common gene found mutated, and the most frequent mutation found is r132H (CGT to CaT) in exon 4 (83-91%) (27) . in gliomas testing negative for the iDH1 mutation, ~18% test positive for iDH2 mutation at exon 4 (29) . in an effort to add additional insight into the genetic makeup of SEGa, we performed sequence analysis of exon 4 in iDH1 and iDH2 for each of our 9 SEGa specimens. We found that all specimens (9/9) were negative for iDH1 and iDH2 mutations at exon 4. our results support the research of Balss and colleagues who found the iDH1 mutation to be absent in all of their SEGa specimens tested (25) . We have also shown that SEGas are negative for the iDH2 mutation at exon 4. This finding is consistent with the impression that infiltrating gliomas typically carry the iDH mutations, while almost all of the non-infiltrative gliomas are wild-type.
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